The Aurobindo Pharma Board approved the Unaudited Financial Results for Q3 FY26, ending December 31, 2025. Key actions included the appointment of Dr.(Mrs.) Punita Kumar Sinha as an Additional Non-Executive Independent Director for three years. Furthermore, the Board approved an investment of ₹66 crores to acquire a 26% stake in Garuda Renewables Private Limited to secure renewable energy supply via a Power Purchase Agreement. The tenure of Dr.(Mrs.) Deepali Pant Joshi as an Independent Director also concluded.
Financial Performance for Q3 FY26
The Board of Directors of Aurobindo Pharma Limited met on February 9, 2026, to consider and approve the standalone and consolidated Unaudited Financial Results for the third quarter and nine months period ended December 31, 2025.
For the quarter ended December 31, 2025 (Unaudited, in million):
- Total Revenue from Operations: ₹86,459.0 million (compared to ₹82,857.0 million in Q2 FY26).
- Profit Before Tax: ₹13,385.2 million (compared to ₹12,759.2 million in Q2 FY26).
- Total Comprehensive Income (Net of Tax): ₹11,375.3 million.
- Basic Earnings Per Share (EPS): ₹15.67 (compared to ₹14.61 in Q2 FY26).
For the nine months ended December 31, 2025 (Unaudited, in million):
- Total Revenue from Operations: ₹2,47,997.4 million.
- Profit Before Tax: ₹38,212.4 million.
- Total Comprehensive Income (Net of Tax): ₹37,567.7 million.
- Basic Earnings Per Share (EPS): ₹44.48 (compared to ₹44.25 in the nine months ended December 31, 2024).
Key Board Approvals and Appointments
Appointment of Additional Director
The Board approved the appointment of Dr.(Mrs.) Punita Kumar Sinha (DIN: 05229262), 63 years old, as an Additional Director, designated as a Non-Executive Independent Director. Her term is for 3 years, effective from February 9, 2026, to February 8, 2029, pending shareholder approval. Dr. Sinha is noted as a seasoned global investor with significant experience in capital markets and ESG governance.
Cessation of Directorship
The Board noted the completion of the 2-year tenure for Dr.(Mrs.) Deepali Pant Joshi (DIN: 07139061) as an Independent Director. Her cessation from the Board was effective from February 10, 2026.
Renewable Energy Investment
The Company approved entering into a Power Purchase Agreement with Garuda Renewables Private Limited (Garuda) to procure renewable energy from hybrid wind and solar sources. In connection with this, the Company will invest ₹66 crores to acquire up to a 26% stake in Garuda. Garuda is a subsidiary of Ecoren Energy Private Limited, focused on developing renewable energy assets.
Amalgamation Proposal
The Board also approved a proposal to file a Scheme of Amalgamation for the merger of Auro Vaccines Private Limited (a wholly owned step-down subsidiary) with Curateq Biologics Private Limited (a wholly owned subsidiary). This merger aims to reduce the number of entities in the group and optimize operational costs.
Exceptional Items Note
The financial results include an exceptional item of ₹653.3 million for both the quarter and nine months ended December 31, 2025. This relates to the impact of newly notified Indian Labour Codes, which resulted in an increased liability aggregation of ₹173.8 million concerning gratuity and leave benefits (presented as past service cost).
Source: BSE
